Evaluation of Safety and Efficacy of Periprocedural Use of Rivaroxaban and Edoxaban in Catheter Ablation for Atrial Fibrillation

Evaluation of Safety and Efficacy of Periprocedural Use of Rivaroxaban and Edoxaban in Catheter Ablation for Atrial Fibrillation - Anticoagulants in atrial fibrillation ablation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019933

Enrollment

150

Registered

2015-11-25

Start date

2015-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Patients taking NOACs upon visiting our hospital were randomly assigned into 2 groups

rivaroxaban and edoxaban. Patients taking NOACs upon visiting our hospital were randomly assigned into 2 groups

rivaroxaban and edoxaban. Warfarin was continued in patients taking warfarin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients who undergo AF ablation

Exclusion criteria

Exclusion criteria: thrombosis in cardium

Design outcomes

Primary

Measure	Time frame
Asymptomatic cerebral microthromboembolism on the day after AF ablation procedure	—

Secondary

Measure	Time frame
hemopericardium in AF ablation	—

Countries

Japan

Contacts

Public ContactYasuhisa Iriki

Kagoshima University Department of Cardiovascular Medicine and Hypertension, Research Field in Medicine and Health Scienc

iriki3@m3.kufm.kagoshima-u.ac.jp099-275-5318

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026